4 terminated, 2 completed, 2 recruiting, 1 withdrawn. 7 Phase 1, 5 Phase 2.
By phase and status
Follow CytomX Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
First In Human Study of CX-801 in Advanced Solid Tumors
CX-801, pembrolizumab - Solid Tumor, Adult | Phase 1 | Recruiting | CytomX Therapeutics | 121 | 2024-08-28 | 2026-08-28 |
First In Human Study of CX-2051 in Advanced Solid Tumors
CX-2051, Bevacizumab - Solid Tumor, Adult | Phase 1 | Recruiting | CytomX Therapeutics | 160 | 2024-04-02 | 2026-07-15 |
A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors
CX-904 - Solid Tumors | Phase 1 | Terminated | CytomX Therapeutics | 83 | 2022-05-16 | 2025-07-14 |
Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
CX-2009, CX-072 - Neoplasms, Breast Neoplasms | Phase 2 | Completed | CytomX Therapeutics | 125 | 2020-12-29 | 2024-01-23 |
PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors
CX-188 - Solid Tumor, Adult | Phase 1 | Withdrawn | CytomX Therapeutics | | 2020-01-01 | 2021-05-05 |
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
CX-072, Ipilimumab - Solid Tumor, Unresectable or Metastatic Melanoma | Phase 2 | Terminated | CytomX Therapeutics | 3 | 2019-11-20 | 2025-12-26 |
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL
CX-2029 - Solid Tumor, Adult, Head and Neck Cancer | Phase 1 / Phase 2 | Completed | CytomX Therapeutics | 133 | 2018-06-15 | 2024-01-23 |
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
CX-2009 - Solid Tumor, Adult, Breast Cancer | Phase 1 / Phase 2 | Terminated | CytomX Therapeutics | 99 | 2017-06-01 | 2024-01-05 |
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
CX-072, ipilimumab, vemurafenib - Solid Tumor, Lymphoma | Phase 1 / Phase 2 | Terminated | CytomX Therapeutics | 196 | 2017-01-19 | 2025-06-17 |
Conditions studied
Neoplasms (5) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Diabetes Mellitus, Insulin-Dependent, 12 (2) · Head and Neck Neoplasms (2) · Esophageal Neoplasms (1) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Melanoma (1) · Ovarian Neoplasms (1) · Recurrence (1) · Triple Negative Breast Neoplasms (1)
Interventions
Ipilimumab (2) · Bevacizumab (1) · CX-2029 (1) · Vemurafenib (1) · pembrolizumab (1)
Countries
United States (9) · Spain (5) · Netherlands (3) · South Korea (3) · United Kingdom (3) · Australia (1) · Poland (1) · Ukraine (1)
Top investigators
Monika Vainorius, M.D. (4) · Monika Vainorius, MD (3) · Lawrence Lu, MD (1) · Yifah Yaron, MD (1)
Results publications
PMID 31953313, PMID 34301808, PMID 34301809